AI assistant
Rua Bioscience Limited — Capital/Financing Update 2025
Jan 27, 2025
66262_rns_2025-01-28_8c23e5b9-1548-476c-bb4f-cba6985be7f2.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
MARKET UPDATE
==> picture [132 x 78] intentionally omitted <==
FOR PUBLIC RELEASE
NZX Limited Wellington
28 January 2025
Rua Bioscience exceeds previous revenue forecast
Rua Bioscience has achieved unaudited revenue of $693,829 for the six months ending December 31, 2024. This result significantly exceeds the company's forecast for the period, reflecting robust growth in our key markets of Germany, Australia, and New Zealand.
During our recent capital raise process in November 2024, Rua had forecast sales of $600,000 for the six-month period. The higher-than-expected demand, particularly in New Zealand and Germany, is the primary driver of the increase.
==> picture [136 x 13] intentionally omitted <==
----- Start of picture text ----- Quarterly sales revenue----- End of picture text -----
==> picture [383 x 190] intentionally omitted <==
----- Start of picture text ----- (Unaudited, NZ$ 000) 4712234523Q3 FY 24 Q4 FY24 Q1 FY25 Q2 FY25Jan - Mar Apr - Jun Jul - Sep Oct - Dec----- End of picture text -----
Both Germany and New Zealand ended the year with exceptionally strong sales of our new dried flower products. Germany in particular, which is Europe’s largest medicinal cannabis market, continues to see rising demand driven by changes to regulations in April last year.
PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com
CEO Paul Naske stated, "This milestone demonstrates the effectiveness of our export-led strategy and provides evidence that we are delivering on our plans."
The company's priorities for the remainder of FY25 include working with suppliers to increase volumes to meet demand in our key markets and expanding our product portfolio.
With a clear roadmap for achieving sustainable revenue and profit, Rua Bioscience is fulfilling its vision of changing lives in our community.
ENDS
The person who authorised this announcement:
Paul Naske Chief Executive Officer [email protected] +64 21 445154
PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com